Checkpoint Inhibitors in First-Line Advanced NSCLC: What Should You Know?
Learn about monotherapy and combination therapy options for patients eligible for first-line immunotherapy.
This activity is intended for hematologists/oncologists and pulmonologists.
The goal of this activity is to educate providers on the appropriate use of immunotherapy for previously untreated patients with non-small cell lung cancer (NSCLC).
Approximate Time to Complete: 30 minutes
Course Available Beginning: Aug. 14, 2017
Developed through a partnership between SITC and Medscape.
 |
 |
- Have increased knowledge regarding the clinical trial data on the use of immune checkpoint inhibitors for first-line management of advanced NSCLC
- Have greater competence related to identifying patients with advanced NSCLC who may benefit from the use of immune checkpoint inhibitors in the first-line setting
- Have greater competence related to managing immune-related adverse events